Literature DB >> 30280066

Netherton Syndrome: A Case Report and Review of Literature.

Hafiz M Kashif Saleem1, Muhammad Faizan Shahid2, Amir Shahbaz3, Atif Sohail4, Muhammad Arslan Shahid5, Issac Sachmechi3.   

Abstract

Netherton syndrome (NS) is a rare autosomal recessive disorder characterized by a triad of congenital ichthyosiform erythroderma (CIE) or ichthyosis linearis circumflexa (ILC), hair shaft abnormalities, and atopic diathesis (elevated serum IgE ). We report a case of a two-year-old boy presented with intractable pruritus, scaling, dry skin and generalized eczematous lesions resistant to atopic dermatitis therapy. Netherton syndrome misdiagnosed as atopic dermatitis due to the presence of eczematous skin lesions and allergic problems. The family counseled about the diagnosis and need of genetic testing for confirmation, but they refused for genetic testing. The patient got treatment with topical corticosteroids and skin moisturizers. There is no cure or satisfactory treatment currently available for NS. Further understanding of the underlying pathophysiology of integumentary changes will lead to more effective treatment. Netherton syndrome should be in the differential diagnosis when characteristic skin manifestation of CIE or ILC, and elevated serum IgE present.

Entities:  

Keywords:  atopic dermatitis; ichthyosiform erythroderma; netherton syndrome; trichorrhexis invaginata

Year:  2018        PMID: 30280066      PMCID: PMC6166913          DOI: 10.7759/cureus.3070

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


Introduction

Netherton syndrome (NS, MIM 256500) is a rare autosomal recessive disorder described by Comel (1949) and Netherton (1958). Congenital ichthyosiform erythroderma (CIE) or ichthyosis linearis circumflexa (ILC), hair shaft abnormalities, and atopic diathesis (elevated serum IgE) characterize it [1,2]. Netherton syndrome is usually misdiagnosed as atopic dermatitis due to the presence of eczematous skin lesions and allergic problems. We present a case of NS with intractable skin manifestations, multiple food allergies, initially treated as atopic dermatitis.

Case presentation

A two-year-old boy referred to our clinic with intractable pruritus, scaling, dry skin and generalized eczematous lesions resistant to atopic dermatitis therapy. Review of his medical record showed he was born at the 37th week of gestation after an uneventful pregnancy to healthy unrelated parents. Shortly after birth, he got treatment for desquamative skin lesions. During the following seven months the desquamation resolved, but ultimately the patient developed generalized, pruritic, erythematous lesions. He got treatment with emollients, topical steroids and tacrolimus creams for severe atopic dermatitis during the next one year. At one year of age, serum IgE levels were 486 IU/ml and 530 IU/ml, respectively. He had no family history of skin disorders. He was allergic to eggs and cow's milk. On physical examination, his skin was dry, and there were erythematous scaly patches on the abdomen, face, and extremities (Figures 1-3).
Figure 1

Ichthyosis linearis circumflexia.

Erythematous, serpiginous and migratory plaques that have a characteristic of double-edged scale at the margin of the erythema.

Figure 3

Ichthyosiform erythroderma.

Generalized erythroderma and greasy, yellow-to-white scale on back and extremities.

Ichthyosis linearis circumflexia.

Erythematous, serpiginous and migratory plaques that have a characteristic of double-edged scale at the margin of the erythema.

Ichthyosiform erythroderma.

Generalized erythroderma and greasy, yellow-to-white scale on back and extremities. The eczematous lesions were not typical of atopic dermatitis. The height and weight were normal. Biochemical tests and serum folate, iron, vitamin B12 and zinc levels were normal. He had dry and short scalp hair. The eyebrows and eyelashes were sparse, nails, palms and mucosal surfaces were intact. Urinary amino acid analysis, immunoglobulins (IgA, IgG, IgM, and IgG), complements (C3, C4) and lymphocyte subset counts (CD3, CD4, CD8, CD14, CD19, CD56) were normal. Serum anti-gliadin IgA and IgG, anti-endomysium IgA, antinuclear antibody (ANA), anti-dsDNA and anti-HIV tests were negative. Thyroid hormone and thyroid autoantibodies were within the normal reference range. The patients had serum eosinophilia and high serum total IgE levels (530 IU/ml). The erythroderma, Ichthyosis linearis circumflexa, elevated IgE along atopic reactions suggest the diagnosis of NS. The patient got treatment with topical corticosteroids and skin moisturizers. The family was counseled about the diagnosis and need of genetic testing for confirmation, but they refused for genetic testing. At six-month follow-up visit, his skin lesion improved but not completely resolved. We keep a close follow-up of the patient.

Discussion

Netherton syndrome is a rare congenital skin disorder. It is a triad of congenital ichthyosiform erythroderma, trichorrhexis invaginata (TI), and an atopic diathesis [1]. It is characterized as premature desquamation of the stratum corneum and impairment of the skin barrier. Mutations in the serine protease inhibitor (SPINK5) gene located on chromosome 5q31-32 result in increased activity of epidermal proteases which cause desquamation. This condition affects one in 100,000 to 200,000 live births [2]. Congenital ichthyosiform erythroderma is the generalized erythroderma and desquamation present at birth. It evolves into a migratory, serpiginous, erythematous, patches with double-edged scales at the periphery. This Ichthyosis linearis circumflexa waxes and wanes throughout the patient’s life and is accompanied by pruritus [3]. The hair shaft abnormality (Trichorrhexis invaginata) due to invagination of the distal portion of the hair shaft into the proximal portion is pathognomonic. The hairs are typically lusterless, dry, sparse, brittle, and are best observed under trichoscopy or trichogram [4]. In our patient, we did not find TI. Though TI is highly specific, its absence does not exclude the diagnosis of Netherton syndrome [5]. During the neonatal period, hypernatremic dehydration and failure to thrive are common complications. NS is inconsistently associated with delayed growth, mental retardation, aminoaciduria, hypoalbuminemia, immune abnormalities, and enteropathy [6]. Because of the defective skin barrier, recurrent bacterial skin infections are common. Atopic manifestations include atopic dermatitis, urticaria, angioedema and elevated serum IgE [7]. NS is misdiagnosed as atopic dermatitis because of atopic skin involvement and mildly elevated IgE levels [6]. Misdiagnosis happens when specific features, such as the shaft hair abnormality, are not evident. In the presence of positive family history and characteristic cutaneous finding, the diagnosis is straightforward. On the other hand, when the clinical features are atypical, the diagnosis delayed or missed. The diagnosis is supported by the identification of a germline SPINK5 mutation by DNA sequencing. However, the cost of performing DNA sequencing analysis limits its use in diagnosis [8]. NS is diagnosed upon the presence of allergic manifestations, and one or more of the following: scaling erythroderma, hair shaft abnormalities, history of NS in a sibling, identification of a germline SPINK5 mutation by DNA sequencing. In some patients, the diagnosis of NS relies upon clinical suspicion and findings [9]. Our patient initially got treatment for atopic dermatitis. Eczema resistant to atopic dermatitis therapy, atopic features, and ichthyosiform erythroderma leads us to consider the diagnosis of NS. The elevated IgE and eczema are also present in Wiskott–Aldrich syndrome, but normal platelet count and immune system rule out this diagnosis. The normal level of Zinc, T and B lymphocytes and the absence of opportunistic infections rule out other possible causes of erythroderma including the inborn errors of metabolism and congenital immunodeficiencies. There is no cure or satisfactory treatment currently available for Netherton syndrome. Topical corticosteroids, topical calcineurin inhibitors, topical retinoids, narrowband ultraviolet B phototherapy, psoralen and ultraviolet irradiation, and oral acitretin are treatment options with varying success. Intravenous immunoglobulin and anti-TNF-α are therapeutic options for severe illness [10-13]. Further understanding of the underlying pathophysiology of skin changes will lead to more effective therapeutic modalities including a possible gene therapy [14].

Conclusions

Netherton syndrome should be in the differential diagnosis when a child presents with generalized erythema, intractable eczematous lesions, and elevated levels of IgE. Despite the lack of genetic testing, diagnosis can be made when characteristic skin manifestation of CIE or ILC, and elevated serum IgE present.
  13 in total

1.  NETHERTON'S DISEASE; TRICHORRHEXIS INVAGINATA (BAMBOO HAIR), CONGENITAL ICHTHYOSIFORM ERYTHRODERMA AND THE ATOPIC DIATHESIS. A HISTOPATHOLOGIC STUDY.

Authors:  R D WILKINSON; G H CURTIS; W A HAWK
Journal:  Arch Dermatol       Date:  1964-01

2.  Netherton's syndrome: successful treatment with isotretinoin.

Authors:  E Lazaridou; Z Apalla; A Patsatsi; A Trigoni; D Ioannides
Journal:  J Eur Acad Dermatol Venereol       Date:  2008-05-08       Impact factor: 6.166

3.  Picture of the month. Comèl-Netherton syndrome without bamboo hair.

Authors:  Daniele Torchia; Lawrence A Schachner
Journal:  Arch Pediatr Adolesc Med       Date:  2011-08

4.  Netherton syndrome: disease expression and spectrum of SPINK5 mutations in 21 families.

Authors:  Emmanuelle Bitoun; Stéphane Chavanas; Alan D Irvine; Lorne Lonie; Christine Bodemer; Mauro Paradisi; Dominique Hamel-Teillac; Shin-ichi Ansai; Yoshihiko Mitsuhashi; Alain Taïeb; Yves de Prost; Giovanna Zambruno; John I Harper; Alain Hovnanian
Journal:  J Invest Dermatol       Date:  2002-02       Impact factor: 8.551

5.  IgE allergen component-based profiling and atopic manifestations in patients with Netherton syndrome.

Authors:  Katariina Hannula-Jouppi; Satu-Leena Laasanen; Hannele Heikkilä; Mirja Tuomiranta; Marja-Leena Tuomi; Sirpa Hilvo; Nicolas Kluger; Sirpa Kivirikko; Alain Hovnanian; Soili Mäkinen-Kiljunen; Annamari Ranki
Journal:  J Allergy Clin Immunol       Date:  2014-08-23       Impact factor: 10.793

6.  Netherton syndrome: report of identical twins presenting with severe atopic dermatitis.

Authors:  Gurkan Kilic; Nermin Guler; Ulker Ones; Zeynep Tamay; Pinar Guzel
Journal:  Eur J Pediatr       Date:  2006-05-03       Impact factor: 3.183

7.  Narrowband ultraviolet B phototherapy associated with improvement in Netherton syndrome.

Authors:  I Maatouk; R Moutran; R Tomb
Journal:  Clin Exp Dermatol       Date:  2012-06       Impact factor: 3.470

8.  Trichoscopy as a diagnostic tool in trichorrhexis invaginata and Netherton syndrome.

Authors:  Maraya de Jesus Semblano Bittencourt; Emanuella Rosyane Duarte Moure; Olga Ten Caten Pies; Alena Darwich Mendes; Monique Morales Deprá; Anna Luiza Piqueira de Mello
Journal:  An Bras Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.896

9.  Phase I study protocol for ex vivo lentiviral gene therapy for the inherited skin disease, Netherton syndrome.

Authors:  Wei-Li Di; Jemima E Mellerio; Catina Bernadis; John Harper; Alya Abdul-Wahab; Sumera Ghani; Lucas Chan; Magdalena Martinez-Queipo; Havinder Hara; Anne-Marie McNicol; Farzin Farzaneh; John McGrath; Adrian Thrasher; Waseem Qasim
Journal:  Hum Gene Ther Clin Dev       Date:  2013-12       Impact factor: 5.032

10.  Infliximab therapy for Netherton syndrome: A case report.

Authors:  Ângela Roda; Maria Mendonça-Sanches; Ana Rita Travassos; Luís Soares-de-Almeida; Dieter Metze
Journal:  JAAD Case Rep       Date:  2017-11-06
View more
  6 in total

1.  MiR-139-5p/ENAH Affects Progression of Hepatocellular Carcinoma Cells.

Authors:  Yueming Zhang; Meng Li; Yinghuan Qiu; Yuhua Wu; Shan Chen; Bin Ni; Ding Tang; Zhouzi Deng; Zhiqiang Hu
Journal:  Biochem Genet       Date:  2022-03-07       Impact factor: 1.890

2.  Chronic symmetrically distributed hyperpigmented plaques in a middle-age woman.

Authors:  Etsubdenk Ajebo; Weston B Wall; Loretta S Davis
Journal:  JAAD Case Rep       Date:  2019-02-27

3.  Phenotypic characteristics of peripheral immune cells of Myalgic encephalomyelitis/chronic fatigue syndrome via transmission electron microscopy: A pilot study.

Authors:  Fereshteh Jahanbani; Rajan D Maynard; Justin Cyril Sing; Shaghayegh Jahanbani; John J Perrino; Damek V Spacek; Ronald W Davis; Michael P Snyder
Journal:  PLoS One       Date:  2022-08-09       Impact factor: 3.752

Review 4.  Proposal for a 6-step approach for differential diagnosis of neonatal erythroderma.

Authors:  E Cuperus; A Bygum; L Boeckmann; C Bodemer; M C Bolling; M Caproni; A Diociaiuti; S Emmert; J Fischer; A Gostynski; S Guez; M E van Gijn; K Hannulla-Jouppi; C Has; A Hernández-Martín; A E Martinez; J Mazereeuw-Hautier; M Medvecz; I Neri; V Sigurdsson; K Suessmuth; H Traupe; V Oji; S G M A Pasmans
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-03-15       Impact factor: 9.228

5.  VEBA: a modular end-to-end suite for in silico recovery, clustering, and analysis of prokaryotic, microeukaryotic, and viral genomes from metagenomes.

Authors:  Josh L Espinoza; Chris L Dupont
Journal:  BMC Bioinformatics       Date:  2022-10-12       Impact factor: 3.307

Review 6.  Netherton Syndrome in Children: Management and Future Perspectives.

Authors:  Federica Barbati; Mattia Giovannini; Teresa Oranges; Lorenzo Lodi; Simona Barni; Elio Novembre; Ermanno Baldo; Mario Cristofolini; Stefano Stagi; Silvia Ricci; Francesca Mori; Cesare Filippeschi; Chiara Azzari; Giuseppe Indolfi
Journal:  Front Pediatr       Date:  2021-05-10       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.